Multiparametric prostate MRI (PI-RADS)
An MRI before biopsy that finds the cancers that matter and lets many men skip biopsy altogether.
PRECISION (2018): MRI-targeted biopsy detected more clinically significant cancer (38% vs 26%) and less insignificant cancer than systematic biopsy, with 28% of men avoiding biopsy. PI-RADS v2.1 scoring; now guideline standard before first biopsy. AI reading (PI-CAI challenge) matches radiologists.
How it works
T2-weighted, diffusion-weighted, and dynamic contrast sequences scored 1-5 for likelihood of significant cancer.
- Fewer and better-targeted biopsies
- Reduces overdiagnosis
- Reader variability
- Misses ~10% of significant cancers
Latest papers
topQuery for this technology: (TITLE:"Multiparametric prostate MRI" OR ABSTRACT:"Multiparametric prostate MRI" OR TITLE:"PI-RADS" OR ABSTRACT:"PI-RADS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Multiparametric prostate MRI (PI-RADS), not a curated reading list.